I'm LongbridgeAI, I can summarize articles.Lexicon Pharmaceuticals reported post hoc analysis from the Phase 3 SOLOIST-WHF trial, presented at ESC Congress 2026. Results indicate sotagliflozin's benefits for worsening heart failure persist across all baseline systolic blood pressure levels, including low readings. The safety profile remained consistent with no increased risk of hypotension or acute kidney injury compared to placebo. These findings support broader use in clinically vulnerable patients, potentially expanding the treatment population.
- Lexicon Pharmaceuticals reported a post hoc analysis from the Phase 3 SOLOIST-WHF trial of sotagliflozin in worsening heart failure. * Results were presented at ESC Congress 2026 on Aug. 30, 2026, with simultaneous publication in JACC: Heart Failure. * Findings showed sotagliflozin benefits held across baseline systolic blood pressure levels, including patients starting with low readings. * Safety profile remained consistent across blood pressure strata, with no signal of higher hypotension or acute kidney injury versus placebo. * Data support broader use in clinically vulnerable heart failure patients, potentially expanding the addressable treatment population if commercialized. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310830PRIMZONEFULLFEED9818200) on August 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)